EXTROVIS
SpecialtyEXTROVIS is a specialty pharmaceutical company focused on Oncology, Infectious Disease, Dermatology.
EXTROVIS's Key Drugs
EXTROVIS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
EXTROVIS's Recent FDA Approvals
New NDA/BLA approvals for EXTROVIS over the last two years — novel drugs only, excluding generics and label supplements.
EXTROVIS's Therapeutic Areas
EXTROVIS's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Infectious Disease, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
EXTROVIS's Top Competitors
EXTROVIS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and PF PRISM CV. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
EXTROVIS Pipeline Snapshot
Active clinical trials for EXTROVIS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1963-07-30
- Latest
- 2025-07-01
- Applications
- 8